Activating mutation of K-ras and inactivation of DPC4 are two common genetic alterations that occur in the development and progression of pancreatic ductal adenocarcinomas (PDAC). A separate common event in PDAC progression is increased expression of phosphotyrosine kinase receptors (PTKRs). In this study, we examined whether activating mutations of K-ras and loss of Smad4 play a role in causing the aberrant expression of PTKRs. Immortalized human pancreas ductal cells (HPNE) were genetically modified by expressing oncogenic K-ras and /or by shRNA knock down of Smad4. EGFR and erbB2 protein levels but not Ron or IGF-1R were substantially up regulated in HPNE cells that express K-ras (GD12) . The increased expression of EGFR in HPNE cells that expressed K-ras (GD12) was mediated by both stabilizing EGFR protein and by increasing EGFR transcription. TGF-β signaling partially suppressed K-ras (GD12) induced EGFR transcription in Smad4 intact HPNE cells; whereas, knockdown of Smad4 in cells expressing Kras (GD12) further enhanced expression of EGFR and erbB2. The up regulation of EGFR and erbB2 was associated with an increase of invasion, which was blocked by a kinase inhibitor of EGFR. This study indicates for the first time, that oncogenic ras and loss of Smad signaling cooperate to up regulate EGFR and erbB2, which plays a role in promoting invasion.
Introduction
Pancreatic cancer is the fourth leading cause of cancer deaths in men or women in the USA with a five-year survival rate of less than 5% 1, 2 . Approximately 90% of these cancers are believed to arise from ductal epithelial cells and are classified as pancreatic ductal adenocarcinomas (PDACs) 3 . Two common genetic alterations that occur in the development and progression of PDAC are activating mutation of K-ras and inactivation of DPC4 by allelic deletion or intragenic mutations. Mutation of K-ras acts as an initiating event in development of PADC; whereas, alterations of DPC4 occur during progression of the disease 4, 5 . DPC4, which codes for Smad4, is necessary for canonical TGF-β/Smad signaling and mutation of Smad4 is one mechanism attributed to loss of TGF-β tumor suppressor activity. TGF-β also signals through Smad independent pathways and the role that these pathways play in tumor progression are not completely understood. A number of studies indicate that there is cross talk between TGF-β and ras pathways; however, whether these pathways interact to cause cancer progression is not well studied 6, 7 .
The phosphotyrosine kinase receptors EGFR and erbB2 are known to be up regulated concomitant with expression of oncogenic K-ras 8 . This up regulation of erbB receptor expression is not caused by amplification or mutations to genes coding for these receptors in PDAC 9 . We recently found that Ron, also a phosphotyrosine kinase receptor belonging to the Met family, was up regulated in PDAC cells as a result of loss of Smad signaling 10 . The current study was undertaken to determine whether activating mutations of ras and loss of Smad4 play a role in the aberrant expression and activation of EGFR, erbB2, IGF-1R and Ron receptors in PDAC.
An activating mutation of K-ras oncogene occurs in up to 95% of PDAC 11 and this mutation is one of the earliest events found in preinvasive pancreatic lesions 5 . Activating mutations of K-ras leads to phosphorylation and activation of other kinases including ERKs and PI3K 12 . The activation of these down stream targets contributes to an increase in cell proliferation and survival 13 . Loss of TGF-β/Smad anti-proliferative and pro-apoptotic responses are common in cancer cells 14 . A number of mechanisms may cause loss of TGF-β tumor suppressor activities and these include allelic deletion or mutation of DPC4 15 , interference of Smad activation by expression of anti-Smads or through inhibitory phosphorylation of Smads by ras 16 , by interaction of Smads with AKT, FOXO or the androgen receptor [17] [18] [19] [20] and, by epigenetic silencing or mutations of TGF-β receptor genes 19 . Of these mechanisms, loss of DPC4 by allelic deletion or intragenic mutation occurs in greater than 50% of PDAC as a relatively late event in tumor progression 5 . A recent study using a genetic mouse models indicate that loss of Smad4 promotes progression of PDAC in the presence of activated K-ras (GD12) 21 . These studies support a role of oncogenic K-ras in the establishment of pre-invasive pancreatic lesions and that a selective pressure to suppress Smad signaling may contribute to disease progression. In this context, it is of interest that concomitant with expression of oncogenic ras is up regulation of EGFR and erbB2 or other phosphotyrosine kinase receptors in preinvasive pancreatic lesions 22 . Moreover, a recent study by Siveke et al 23 indicates, using a genetic mouse model, that up regulation of EGFR signaling is necessary for progression of preinvasive pancreatic lesions to invasive disease.
Based on these results we sought to determine whether the initiating event of oncogenic ras expression and/or loss of Smad4 play a role in up regulating phosphotyrosine kinase receptor expression and activity. To examine this possibility, primary human cells derived from the ducts of the pancreas and immortalized with hTERT were used. This immortalized cell line model was previously described and is positive for the expression of nestin, is diploid and expresses wild type p16 Ink4a , p53 and K-ras and is referred to as human pancreas nestin expressing cells or HPNE 24 . To block ras-induced senescence and allow oncogenic ras expression, these cells were modified to produce the HPV16, E6 and E7 proteins. From these E6/E7 cells (thereafter referred as HPNE), isogenic matched cell lines were generated by expressing K-ras (G12D) 25 and/or by knocking down Smad4. Expressing K-ras (G12D) was sufficient to substantially up regulate the expression of both EGFR and erbB2 but not Ron or IGF-1R. Knock down of Smad4 in cells expressing K-ras (GD12) further enhanced expression of these receptors. This study indicates for the first time, that oncogenic ras and loss of Smad signaling cooperate to up regulate EGFR and erbB2, which plays a role in promoting invasion.
Materials and Methods

Cell lines and reagents
The hTERT-immortalized human pancreas nestin expressing cell line (hTERT-HPNE) modified to express E6/E7 alone (refer therein as HPNE) or E6/E7 in conjunction with oncogenic K-Ras (refer therein as HPNE/Ras) were obtained from Michel M. Ouellette (University of Nebraska Medical Center, Omaha, Nebraska). From these two cell lines, we generated the isogenic matched cell lines in which Smad4 is silenced by infecting these cells with a pSuper/Smad4 shRNA plasmid. A stable pool was selected by the limited dilution and knocking-down Smad4 expression was confirmed by Western blot. These cell lines were designated as HPNE/shSmad4 or HPNE/Ras/shSmad4, respectively. All the cell lines were maintained in medium D [3 parts DMEM (Invitrogen, Grand Island, NY) and 1 part M3F medium (INCELL Corporation LLC, San Antonio, TX) supplemented with 5% FBS 24 ]. The human recombinant TGF-β1 and human recombinant EGF were purchased from R&D Systems (Minneapolis, MN). The EGFR inhibitor, AG1478, the MEK inhibitor, PD 98059, PI3K inhibitor, LY 294002 and cycloheximide were purchased from Calbiochem (San Diego, CA).
Luciferase reporter assays
Cells were plated at a density of 5 × 10 4 cells/well in 24 well plates 24 hours before transfection. The TGF-β responses of these cells were determined by a luciferase reporter construct of TGF-β response elements (3TP-Lux) assay 10 . For the EGFR promoter activity, cells were transfected with 0.3 μg/well of EGFR promoter-luciferase reporter plasmid, pER1-luc (kindly provided by Dr. Alfred Johnson, Laboratory of Molecular Biology, CCR, NCI, NIH). 24 hours after transfection, cells were treated with 5 ng/ml TGF-β1 or vehicle control for 24 hours. EGFR promoter luciferase activities were measured using Luciferase Assay System (Promega) and normalized to protein levels.
MTT cell proliferation and soft agar assays
Cell proliferation rate was determined as described previously by a MTT [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide] assay 10 . To determine anchorageindependent growth, soft agar assays were performed. Briefly, 6 well plates were coated with 0.8 % noble agar (Becton Dickinson, Sparks, MD) and 2 × 10 4 cells were seeded per well in 0.4% agar in medium D and treated with 5 ng/ml TGF-β1 or vehicle control for 14 days. During the culture period, cells were fed with 500 μl of fresh medium with the treatment every 5 days. At the end of the culture, cells were stained with 0.5 mg/ml MTT in culture medium for 4 hours.
Western blot analyses and immuno-fluorescence staining
Western blot analysis was performed as described previously (26) . Primary antibodies used were as follows: anti-Smad3 was from Zymed (Carlsbad, CA); anti-Smad2/3 was from BD Biosciences (San Jose, CA); anti-Smad4 was from Santa Cruz (Santa Cruz, CA); anti-EGFR and anti-phos-EGFR Tyr1068 , anti-erbB2 and anti-phos-erbB2 Tyr1248 , anti-ERK1/2 and antiphos-ERK1/2 Thr202/Tyr204 , anti-AKT and anti-phos-AKT Ser473 were purchased from Cell Signaling Technology (Beverly, MA). Anti-phos-Smad2 was purchased from Chemicon (Temacula, CA). Horseradish peroxidase-conjugated secondary antibodies were purchased from Amersham Biosciences (Piscataway, NJ). For immuno-fluorescence staining, cells grown on 8-well chamber slides were fixed in 4% paraformaldehyde for 15 minutes at room temperature and permeabilized with 0.1% Triton X-100. Non-specific sites were blocked with 5% goat serum. The primary antibody to EGFR was from Santa Cruz and Alexa Fluor-488 goat anti-rabbit IgG was from Molecular Probes (Eugene, OR). Cell nuclei were stained with 1 μg/ml hoechst 33342 and the slides were then mounted with PremaFluo aqueous mountant (Immuno Thermo, Pittsburgh, PA) and visualized using a Nikon Eclipse TE200 fluorescence microscope.
Quantitative reverse transcription-PCR
Total RNA was isolated from cells with indicated treatments using Trizol reagent (Invitrogen). 200 ng of total RNA was reverse transcribed into cDNA and subjected to real time PCR reaction with CYBR Green Master Mix (Applied Biosystems) following the manufacturer's instruction. The primer sequences for EGFR are as follows: forward 5′-AACTGTGAGGTGGTCCTTGG-3′ and reverse 5′GTTGAGGGCAATGAGGACAT-3′ 27 . β-actin mRNA was amplified simultaneously for an endogenous control. The primer sequences for β-actin were used as described previously 10 .
Matrigel invasion Assays
The invasive behavior of cells was analyzed by Matrigel invasion assays as described previously 10 . 3 × 10 4 cells/well were plated in a 24-well Matrigel invasion chambers (Becton Dickinson Labware, Franklin Lakes, NJ) in 0.5 ml of serum free medium D. The outer chambers contained 0.7 ml of medium D supplemented with 5% FBS. 48 hours later, the cells on the top surface of the membrane were gently removed with cotton swaps. The cells migrating to the undersurface of the membrane were fixed in 70% ethanol and stained with crystal violet. The invasion values were determined by eluting crystal violet in 10% acetic acid and the absorbance were taken using a Fluostar Optima Plate Reader at 595 nm.
Results
The effect of expressing oncogenic K-ras and knocking down Smad4 on expression of PTKRs in immortalized HPNE cells
The immortalized human pancreas ductal derived cell line, HPNE was used to examine whether expression of oncogenic ras and/or loss of Smad4 may contribute to aberrant expression of PTKRs associated with PDAC. Exponentially growing isogenic matched cell lines, HPNE, HPNE/Ras, HPNE/shSmad4, and HPNE/Ras/shSmad4, and PDAC cell lines were harvested and analyzed after Western blotting for expression of EGFR, erbB2, Ron and IGF-1R. Figure 1. A. compares the expression of these receptor kinases in HPNE and six PDAC cell lines. As anticipated, the expression of PTKRs was low in HPNE cells compared to PDAC cell lines (Fig. 1A) . As shown in Fig.1B , Smad4 was efficiently knocked-down by shRNA in both HPNE/shSmad4 and HPNE/Ras/shSmad4 cells while expression of Smad2 and Smad3 were not affected. Knock down of Smad4 alone did not appear to increase the expression of EGFR, erbB2, or Ron kinase (Fig. 1B) . Knock down of Smad4 did cause a subtle up regulation in expression of IGF1-R ( Fig.1.B) . The expression of oncogenic K-ras caused an increase of EGFR and erbB2 expression and interestingly, knock down of Smad4 in HPNE cells that express K-ras (GD12) further increased the expression of EGFR and erbB2 to a level greater than that seen by expression of oncogenic K-ras alone (Fig.1B) . The expression and localization of EGFR and erbB2 was further determined by immunofluorescence. The results were similar for both EGFR and erbB2 and a representative pattern of immunofluorescent detection for EGFR is shown in Fig. 1 .C. HPNE and HPNE/shSmad4 cells showed little or no EGFR detection; whereas, increasing cell surface expression of EGFR is seen in HPNE/Kras modified cells and HPNE/Ras/ shSmad4 cells ( Fig. 1.C) . The expression of oncogenic K-ras and/or knock down of Smad4 in HPNE did not induce the expression of Ron (Fig. 1.B) .
Knock down of Smad4 and expression of oncogenic K-ras cooperates to increase tumorigenicity and invasiveness
The TGF-β responsiveness of HPNE and HPNE modified cells was examined using 3TP-Lux assays ( Fig. 2A) . Knock down of Smad4 expression as well as expression of Kras (GD12) decreased Smad-dependent TGF-β response. The HPNE and HPNE modified cell lines were further assessed for proliferation rates, anchorage-independent growth and invasiveness. HPNE and HPNE/shSmad4 cells grew slower than cells expressing Kras (GD12) (Fig. 2B) . It is interesting that knock down of Smad4 (HPNE/shSmad4) did not increase cell growth suggesting that autocrine TGF-β did not play a role in the exponential growth of these cells. Expression of K-ras (GD12) in HPNE cells caused a robust increase in the overall growth rate and knock down of Smad4 in oncogenic ras expressing cells did not further enhance the proliferation rate (Fig. 2.B) . HPNE and HPNE/shSmad4 cells did not form colonies in soft agar (Fig. 2.C) . The expression of K-ras (GD12) in HPNE cells promoted growth in soft agar and a combination of expression of oncogenic K-ras and knock down of Smad4 further increased the numbers of colonies formed in soft agar (Fig.  2.C) . Treatment of cells with exogenous TGF-β reduced growth in soft agar in HPNE/Ras cells, whereas, knock down of Smad4 inhibited this effect (Fig. 2.C) . Matrigel invasion assays were used to examine the invasion properties of the HPNE and HPNE modified cells. Unlike cell proliferation, knock down of Smad4 was sufficient to increase cell invasion and the expression of oncogenic K-ras also caused an increase in invasion (Fig. 2. D) . Similar to that seen for soft agar assays, addition of TGF-β partially suppressed invasion in onocgenic K-ras expressing cells but not in the same cells expressing shSmad4 RNA (Fig. 2.D) . HPNE/ Ras/shSmad4 cells compared to HPNE/Ras cells showed an even greater level of invasion ( Fig. 2.D) .
Increased invasion of HPNE cells modified by Smad4 knock down or expression of oncogenic ras requires EGFR signaling
An up regulation of EGFR and erbB2 expression was observed in K-ras (GD12) expressing cells (HPNE/K-Ras) and knock down of Smad4 in these cells (HPNE/Ras/shSmad4) further increased the expression of these receptors ( Fig.1.B) . EGFR/erbB2 signaling was further assessed to determine if up regulation of erbB signaling was required for the increase in invasion observed for HPNE/shSmad4, HPNE/Ras and HPNE/Ras/shSmad4 cells. Cells were stimulated with human recombinant EGF and EGFR/erbB2 activation was determined by detecting tyrosine phosphorylation at Tyr 1068 for EGFR and Tyr 1248 for erbB2. Compared to HPNE cells, HPNE/shSmad4 and HPNE/Ras cells showed an increase in EGFR/erbB2 phosphorylation (Fig. 3.A) . The increase of phosphorylation of EGFR and erbB2 in HPNE/Ras cells is consistent with the increase in levels of expression of these receptors. An increase of phosphorylation of EGFR and erbB2 was also seen in HPNE/ shSmad4 cells; although it is not clear whether this resulted from a subtle increase in these receptors (Fig 1.B) . Knock down of Smad4 in HPNE/Ras cells further enhanced the levels of expression and phosphorylation of EGFR and erbB2 (Fig. 3A) . Consistent with activation of erbB receptors, an increase in phosphorylation of ERK1/2 and AKT, known signaling targets of erbB receptors, was observed for HPNE/Ras/shSmad4 cells following stimulation with human recombinant EGF (Fig. 3.A) . Next, we determined whether inhibiting EGFR or its down stream signaling targets could block cell invasion. HPNE/shSmad4 and HPNE/Ras/ shSmad4 cells were treated separately with an EGFR inhibitor (AG1478), MEK inhibitor (PD98059) and a PI3K inhibitor (LY294002). Cell invasion was significantly diminished by inhibiting EGFR or PI3K, but not by inhibiting MEK (Fig.3.B) . We confirmed that the EGFR inhibitor, AG1478, effectively and specifically inhibited Tyr 1068 phosphorylation of EGFR and phosphorylation of its down stream effectors, ERK1/2 and AKT (Fig. 3.C) . Treatment of cells with the MEK inhibitor, PD 98059 and the PI3K inhibitor, LY 294002 specifically blocked phosphorylation of Erk1/2 and AKT respectively (Fig 3.D) . Treatment of HPNE/Ras/shSmad4 cells with PD98059 or LY294002 caused a decrease in the level of total EGFR suggesting that these pathways are important for EGFR expression. However, the level of decrease in EGFR was not likely sufficient to cause the dramatic reduction observed for activation of MEK and AKT, respectively (Fig. 3.D) . These results suggest that EGFR signaling and its down stream targets PI3K are important for driving invasion in HPNE/shSmad4, HPNE/Ras and HPNE/Ras/shSmad4 cells.
Oncogenic K-ras increases EGFR transcription and protein stability and Smad4-dependent TGF-β signaling suppresses EGFR transcription
The effect of TGF-β signaling on EGFR and erbB2 expression was further examined in HPNE and in isogenic clones of HPNE modified cells by knock down of Smad4 and/or expression of oncogenic K-ras. Treatment with exogenous TGF-β partially suppressed the expression of EGFR and erbB2 in HPNE and in HPNE/Ras cells but not in Smad4 knock down cells (Fig. 4.A) . As shown in figure 1 and again in figure 4 .A, the steady state level of expression of these receptors was higher in cells expressing oncogenic K-ras. These studies suggest that oncogenic K-ras contributes greatly to aberrant expression of EGFR and erbB2 and that Smad4-dependent signaling negatively regulates the expression of these receptors.
The level at which oncogenic K-ras positively and Smad4-dependent signaling negatively regulates EGFR expression was further examined. First the half-life of EGFR protein was determined. The overall expression level of EGFR was greater in HPNE expressing oncogenic K-ras (Fig. 4.B. ). Expression of oncogenic K-ras significantly increased the halflife of EGFR protein in HPNE cells (3.6 hrs. in HPNE and 3.9 hrs. in HPNE/shSmad4) compared to cells expressing oncogenic K-ras (6.2 hrs. in HPNE/Ras and 6.9 hrs. in HPNE/ Ras/shSmad4). Thus, these experiments indicate that oncogenic K-ras causes an increase in expression of EGFR, at least in part, by increasing the stability of this protein.
The effects that oncogenic K-ras and loss of Smad4 has on EGFR mRNA expression were also examined. Similar to that seen for protein levels, treatment of cells with TGF-β reduced the amount of mRNA for EGFR in HPNE and HPNE/Ras cells and knock down of Smad4 prevented TGF-β reduction in EGFR mRNA (Fig. 4.C) . Expression of oncogenic K-ras also increased EGFR mRNA levels (Fig 4. C) . EGFR promoter activity was compared for HPNE and HPNE modified cells. The results of the EGFR promoter assays indicate that oncogenic K-ras increased EGFR mRNA by increasing the transcription of the EGFR gene (Fig. 4.D) . The decrease of EGFR mRNA expression in response to TGF-β in Smad4 intact cells was also examined by EGFR promoter assays. TGF-β treatment reduced EGFR promoter activity of HPNE and HPNE/Ras cells (Fig. 4.D) . Knock down of Smad4 in HPNE and HPNE/Ras cells prevented TGF-β mediated suppression of EGFR promoter activity. A likely explanation for the increase in expression of EGFR seen in HPNE/Ras/shSmad4 cells compared to HPNE/Ras cells is the loss of Smad dependent transcriptional repression of the EGFR gene. Thus, canonical TGF-β signaling plays a role in regulating EGFR transcription and expression.
Discussion
Studies of human PDAC specimens and genetic mouse models of PDAC have lead to a better understanding of the genetic progression of this cancer 5, 28 . Despite this wealth of genetic data, the knowledge of how these alterations impact the biology and progression of PDAC is largely correlative. Here we used a systematic approach for generating genetic alterations, common to PDAC, in immortalized pancreas ductal cells (HPNE). These isogenic cell line models are amendable for studying how these alterations influence expression of PTKRs, tumorigencity and cell signaling. Specifically, HPNE cells were altered by expressing K-ras GD12 , by knocking down expression of Smad4 or by generating both alterations in the same cell line.
We found that expression of K-ras GD12 up regulated the expression of EGFR and erbB2 and induced an invasive phenotype but did not change the expression of Ron or IGF-1R. Knock down of Smad4 in HPNE increased the activation of EGFR and erbB2 but to a much lesser extent than did the expression of K-ras GD12 . Although not further investigated in the present study, knock down of Smad4 caused a slight increase in IGF1-R expression but had no effect on the expression of Ron. The finding that loss of Smad4 did not increase expression of Ron was somewhat surprising in light of our recent study showing that Smad4 is a negative regulator of Ron expression in PDAC 10 . This suggests that loss of Smad4 by itself is not sufficient to up regulate Ron expression and that other oncogenic events leads to aberrant Ron expression in PDAC.
Interestingly, knock down of Smad4 in K-ras GD12 expressing HPNE cells further up regulated EGFR and erbB2 and caused a further increase inactivation of their down stream signaling targets ERKs and AKT. This increase in signaling induced invasion, which could be prevented by inhibitors of EGFR or PI3K. These data suggests that Smad4 normally suppresses ras induced up regulation of EGFR and erbB2 and that loss of Smad signaling contributes to an increase in ras-induced up regulation of these receptor kinases. It is noted that an increase in EGFR promoter activity or EGFR protein stability could not totally account for the additive increase in EGFR expression observed after knock down of Smad4 in HPNE/ras cells. It is possible that sensitivity of the assays used may be limited especially when the activity is relatively high.
These isogenic cell lines of HPNE provided models to further compare the tumorigenic effects of K-ras (GD12) in HPNE cells that possessed intact Smad components with isogenic matched cells deficient in Smad4. TGF-β signaling is altered in cancer cells and the current dogma suggests that there is a switch of this pathway from tumor suppression to tumor promotion 29 . TGF-β signals through Smad dependent and Smad-independent pathways. Smad dependent pathways are essential for tumor suppressor activities in normal epithelial cells and several studies suggest that Smad signaling contributes to tumor progression in some tumor types 30 . Baselga et al. reported that Smad signaling was critical for bone metastasis in mouse models of breast cancer 31 . Danielpour and his colleagues indicate that Smad signaling and EGFR cooperate to promote tumor growth in prostate cancer cells 32 . However, we previously reported that restoring Smad4 in Smad4 deficient PDAC cells reduced metastasis suggesting that TGF-β may maintain some tumor suppressor activity in those PDAC that possess an intact Smad pathway 26 . Studies by others indicate that oncogenic K-ras represses Smad signaling, suggesting that Smad-mediated tumor suppressor activity may be attenuated independent of mutation of DPC4 16, 33 . TGF-β reduced invasion in HPNE/Ras cells indicating that some level of Smad-mediated tumor suppressor activity was presence in cells that possess oncogenic ras signaling. A role for Smad signaling in suppressing oncogenic K-ras induced tumorigencity is supported by a recent study indicating that inactivation of Smad4 accelerated K-ras GD12 induced pancreatic cancer development and progression 21 . Genetic studies in mice indicate that loss of Smad4 is not sufficient to cause the development of PDAC but contributes to tumor progression in the presence of additional oncogenic alterations 34, 35 , Lacobuzio-Donahue et al. 36 recently reported that patients whose tumors have mutation of DPC4 showed widespread metastatic disease compared to the more locally destructive disease of PDAC observed for patients whose tumors express wild type Smad4. Our study supports and adds to these findings by showing that Smad4 dependent TGF-β signaling negatively regulates EGFR signaling in HPNE. Loss of Smad4 enhances oncogenic K-ras induced up regulation of EGFR and erbB2 and that aberrant EGFR activity is necessary for tumorigenicity and invasion caused by oncogenic K-ras.
Increase in expression and activation of EGFR and other erbB family members occurs as an early event in the pancreatic neoplasia although the mechanism by which this occurs is not clear 5, 37 . A recent study indicates that expression of oncogenic K-ras in rat pancreas epithelial cells increase of expression of EGFR 38 . Our study is in agreement with the genetic progression model of pancreatic cancer and directly links oncogenic K-ras with up regulation of EGFR and erbB2. Moreover we found that loss of Smad4 that occurs as a late event during progression of PDAC further enhances the aberrant expression of EGFR and erbB2. This suggests that enhancement of EGFR signaling is characteristic of PDAC progression. Moreover, Smad4-dependent TGF-β signaling plays a role in suppressing rasinduced EGFR expression and that loss or attenuation of Smad4-dependent signaling represents an event that leads to further enhanced EGFR signaling and invasion.
In summary, this study supports the correlative pathologic data indicating that loss of Smad4 in PDAC is associated with more aggressive and invasive phenotype. The data are consistent with concomitant up regulation of EGFR and erbB2 as a result of oncogenic K-ras signaling that occurs early in pancreatic neoplasia. We found that Smad4-dependent signaling attenuated oncogenic K-ras induction of EGFR transcription and that TGF-β suppressed invasion and anchorage independent growth in Smad4 intact HPNE cells that express Kras GD12 . This suggests that Smad-dependent signaling may partially suppress ras-mediated transcription of EGFR and erbB2. This study also implies that some level of TGF-β tumor suppressor activity is maintained in early stages of pancreatic neoplasia and that loss of Smad4 facilitates tumorigenic effects mediated by oncogenic K-ras signaling, in part, by up regulating EGFR/erbB2 signaling. A. TGFβ suppressed EGFR expression in Smad4 intact HPNE cells. Cells were treated with vehicle or 5 ng/ml of TGF-β1 for 24 hours and then the levels of EGFR and erbB2 were analyzed by Western blot. Phosphorylation of Smad2 was shown to indicate TGF-β responsiveness. β-actin was used for protein loading control. B. Oncogenic K-ras prolonged the EGFR protein half-life. Cells were treated with 20 μg/ml of cycloheximide for the indicated time period. The upper panel, total cell lysates were analyzed by Western blot with an antibody against EGFR. β-actin was used for protein loading control. The lower left panel, densitometry analysis of the levels of EGFR expression shown in the upper panel. The relative EGFR levels were normalized to β-actin levels. The lower right panel, EGFR protein half-lives were determined from the densitometry data and presented as log percentage of the initial EGFR level at time "0". C and D. Oncogenic K-ras promoted, whereas Smad4 suppressed EGFR transcription. C. Cells were treated with 5 ng/ml of TGFβ1 for 24 hours and total RNA was isolated. 200 ng total RNA was subjected to reverse transcription and real-time PCR with SYBR Green mix. The data were presented as relative EGFR mRNA levels compared to the level of control HPNE cells. D. Cells were transfected with EGFR promoter luciferase reporter construct (pER-1) and treated with vehicle control or 5 ng/ml TGF-β for 24 hours. The EGFR promoter activities were measured 48 hours after transfection and normalized to protein levels. Relative EGFR promoter activities were presented as mean ± SD of a representative experiment performed in triplicate. Summary of the proposed regulation of EGFR expression levels in HPNE cells by oncogenic ras and Smad pathways. Signaling by oncogenic ras up regulates the transcription of EGFR and promotes the stability of ras protein. Smad signaling is a negative regulator of EGFR transcription. Thus, signaling by oncogenic ras and loss of Smad4 in HPNE cells cooperate to increase the level of EGFR causing an increase in invasion.
